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Abstract By its strategic position at the interface between
blood and tissues, endothelial cells control blood fluidity and
continued tissue perfusion while simultaneously they direct
inflammatory cells to areas in need of defense or repair. The
endothelial response depends on specific tissue needs and
adapts to local stresses. Endothelial cells counteract coagula-
tion by providing tissue factor and thrombin inhibitors and
receptors for protein C activation. The receptor PAR-1 is
differentially activated by thrombin and the activated protein
C/EPCR complex, resulting in antithrombotic and anti-
inflammatory effects. Thrombin and vasoactive agents release
vonWillebrandfactorasultra-largeplatelet-bindingmultimers,
which are cleaved by ADAMTS13. Platelets can also facilitate
leukocyte-endothelium interaction. Platelet activation is pre-
vented by nitric oxide, prostacyclin, and exonucleotidases.
Thrombin-cleaved ADAMTS18 induces disintegration of
platelet aggregates while tissue-type plasminogen activator
initiates fibrinolysis. Fibrin and products of platelets and
inflammatory cells modulate the angiogenic response of
endothelial cells and contribute to tissue repair.
Keywords Endothelial cell.Antithrombotic.Activated
protein C.von Willebrand factor.ADAMTS13.
Fibrinolysis.Inflammation
Introduction
The maintenance of blood fluidity is controlled by the inner
lining of the circulatory system, a thin layer of cells, the
endothelium. Endothelial cells cover the entire vasculature of
vertebrates, and thus, form a hemocapatible blood container
with a large surface, which has been estimated to amount
3,000–6,000m
2 [1]. Although on many places not more than
0.2 μm thick, endothelial cells form a diffuse tissue of about
720 g in an adult person. Most of these cells are
microvascular endothelial cells, and over 600 g of them
cover the surface of capillaries [2]. In the capillaries,
exchange of nutrients and hormones occurs facilitated by
the exposure of a large endothelial surface area to a relatively
small volume of blood. In contrast, in arteries and veins the
ratio between surface and blood volume is 100- to 500-fold
less. Furthermore, the shear forces evoked by the flowing
blood vary in different types of blood vessels. Consequently,
considerable variation exists in the regulation of general and
specific functions between arteries, veins, arterioles, post-
capillary venules, and capillaries. In addition, specific tissue
demands also underlie a large variation between microvas-
cular endothelial cells from various tissues [3].
This review focuses on the role of the endothelium in the
regulation of hemostasis and thrombosis, and how an
activated status of the endothelium, in particular induced by
inflammation, can cause proper and improper adaptations of
the endothelial phenotype.
General functions of the endothelium
In relation to their role as a gatekeeper between blood and
tissues, endothelial cells are equipped with several general
main functions while in addition many specific functions
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endothelial cells are required to prevent thrombus forma-
tion. Specific functions and adaptations of endothelial cells
aim at maintaining blood fluidity and preventing thrombus
formation. This isonly possiblebecause the endothelium also
actively controlsthe extravasation offluid, solutes,hormones,
and macromolecules[4], as well as that of platelets and blood
cells. This guarantees the availability of appropriate amounts
of clotting factors and platelets. Furthermore, the endotheli-
um, together with the smooth muscle cells, plays an
important role in the control of perfusion of specific tissues
and the blood tension by local vasoregulation. This is further
facilitated by the responsiveness of endothelial cells to
vasoactive agents, and—in particular in the lung—by
involvement of the endothelium in the conversion and
catabolism of vasoactive agents. Another general feature of
endothelial cells is that they can become activated by
inflammatory cytokines, triggers of the innate and acquired
immune response, and by other stresses such as hypoxia and
metabolic stress [5–8]. Such activations induce the transcrip-
tion of new genes, which enable endothelial cells to offer a
new repertoire of activities and receptors. Endothelial cells
control the recruitment of leukocytes in areas, where these
inflammatory cells are needed, in particular by expressing
specific proteins cell adhesion molecules. They adapt their
metabolism according to oxygen tension and metabolic
needs. In inflammation, various functions of the endothelium
are pivotal and well recognized from features such as tissue
swelling due to a reduced barrier function, vasodilation,
which also causes the red color, increased leukocyte
infiltration, and alterations in the control of coagulation and
thrombus formation into a more procoagulant direction.
Furthermore, endothelial cells are involved in the healing
process after wounding or inflammation by being the vector
of angiogenesis, the formation of new blood vessels, which
is essential for proper formation of granulation tissue and
tissue repair as well as for re-canalization of mural and
obstructing fibrin clots.
Vessel- and tissue-specific functions of endothelial cells
Related to differences in shear forces by the flowing blood,
blood oxygenation, and smooth muscle content, arteries and
veins display marked differences in their response to
vasoactive agents and inflammatory cytokines. While the
regulation of vasodilation is fast in arteries, it is consider-
ably slower in veins. Arterial shear forces induce the
transcription factor KLF2 and suppress inflammatory
activation, a property that is lost in atherosclerosis-prone
areas with disturbed blood flow [9–11]. The different shear
forces also bear impact on the nature of thrombi, which are
platelet-rich (white) in the arterial tree, while more fibrinous
and red in veins. Veins also contain valves, in particular in the
lower limbs, which often become initiation sites for a venous
thrombus, because of disturbed flow, local hypoxia, or other
unknown reasons. The high availability of the fibrinolysis
regulator tissue-type plasminogen activator (t-PA) may con-
tribute the fact that these thrombi make little contact to the
endotheliumwhile extendingand growing inthebloodstream,
by which they become prone to form large emboli.
A comparison of endothelial cells cultured from arteries,
veins, and microvessels from various tissues demonstrated that
not only arteries and veins displayed distinct differences but in
particular,microvascular endothelial cells hadspecificgenomic
properties with additional differences at the tissue level
[12]. This is reflected in different expression of surface
receptors, such as the microvascular-specific expression of
α1β1-integrins [13] and plasmalemma vesicle-associated
protein-1, a leukocyte trafficking molecule recognized by
the antibody Pal-E [14]. Tissue-specific endothelial expres-
sion of γ-glutamyl-transpeptidase and monoamine oxidase
was observed in brain microvessels. Bone marrow endothelial
cells express E-selectin constitutively, while in other types of
endothelium E-selectin synthesis requires inflammatory acti-
vation. The lymphocyte receptor MadCam is found in
endothelium of lymph nodes and Peyer’s patches vessels of
the intestine [15]. Fenestrae and heparin receptors are found
in liver sinusoids. Thrombomodulin, while abundantly
present in other endothelial cells, is poorly expressed or
absent in brain microvascular and liver sinusoidal endothelial
cells [16]. Differences between microvascular endothelial
cells in heart, kidney, and lungs were recently reviewed by
Aird [17]. In addition, the response to inflammatory cytokines
and vasoactive agents differs between various vascular beds,
among which the postcapillary venules often respond most
pronounced. Similarly, the microvascular endothelium of
different tissues responds differently in this respect, thus
explaining tissue-specific pathological responses, such in
Shiga toxin induced hemolytic uremic syndrome, where the
Shiga toxin receptor Gb3 is increased by tumor necrosis
factor alpha (TNF-α) specifically in kidney glomerular
endothelial cells making them prone to damage [18].
Cellular mechanisms of endothelial regulation
and adaptation
Endothelial cells respond and adapt their phenotype atvarious
time intervals according to the nature of the stimulus [5, 19].
These responses comprise acute release of endothelial
products; immediate response to hypoxia by activation of
hypoxia-inducible factors HIF-1 and HIF-2 and subsequent
induction of new genes; induction of new endothelial
receptors and secreted proteins by inflammatory cytokines,
endotoxin, activation of toll-like receptors, and CD40 ligand;
94 Semin Immunopathol (2012) 34:93–106shedding of surface receptors following these reactions; and
participation in immunological reactions.
The endothelial cells are able to respond within minutes to
vasoactive agents, thrombin, or TNF-α. This acute response
follows receptor-mediated cell signaling accompanied by
influx of calcium ions and induction of various types of
phosphorylations, which result on the one hand in activation
of enzymes that generate NO, prostacyclin/prostaglandin E2
and, in certain conditions endothelin-1, and on the other hand
in the recruitment of vesicles with pre-formed proteins to the
plasma membrane. The Weibel–Palade bodies are specific
representatives of these storage organelles and release von
Willebrand factor (VWF), P-selectin, and angiopoietin-2,
which are involved in platelet binding, leukocyte recruitment,
and inflammation modulation, respectively. But also the
content of other vesicles containing the fibrinolysis regulator
t-PA or the vasoconstrictor endothelin-1 can become released
simultaneouslydepending on the vesseltype. Acute release of
endothelial products by thrombin is largely mediated via the
protease-activated receptor-1 (PAR-1). It should be noted
that earlier exposure to low thrombin concentrations causes
activation of protein C, which modifies the response of
PAR-1 (see below). Furthermore, activation by vasoactive
agents cause a several minutes during transient impairment
of endothelial barrier function in postcapillary venules.
When endothelial cells become hypoxic, they respond
immediately by rescue of hypoxia-inducible factors HIF-1α
and HIF-2α (Fig. 1, lower part). These factors are
continuously synthesized and degraded in the proteasomes
after modification by prolyl and asparagyl hydroxylations
and interaction with von Hippel–Lindau protein [6, 20].
Because the HIF prolyl hydoxylases require oxygen for
their activity, the absence of sufficient oxygen results in the
rescue and nuclear translocation of the HIF-α-subunits.
Subsequent dimerization with HIF-1β/ARNT results in
either HIF-1 or HIF-2 that act via specific responsive
elements as transcription factors for many, probably 600–
1,800 genes. They comprise genes involved in metabolism,
cell survival,angiogenesis,matrixdeposition,andrecruitment
ofleukocytesandprogenitorcells,suchasSDF-1andCXCR4
[6]. While HIF-1α is ubiquitously present in cells, the
synthesis of HIF-2α is restricted to a limited number of cell
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Fig. 1 Adaptation of endothelial cells to inflammatory stimuli and
hypoxia. Upper part, the classical (canonical) NFκB pathway is
activated by various mediators and their receptors and involves
liberation of the NFκB (p65/p50) after phosphorylation and degradation
of IκBα,- β, and -ε (indicated as IκBα). In addition, lymphotoxin and
CD40 ligand can further influence endothelial activation probably via
the non-canonical NFκB pathway or part of it. Further details are given
in the text. Lower part, left, the two prolines of the α-subunits of HIF-1
and HIF-2 are hydroxylated by proline hydoxylase-2 (PHD-2), which
requires oxygen (O2), after which they bind do von Hippel–Lindau
(VHL) protein and are degraded in the proteasome. The lack of oxygen
(lower part, right) causes rescue of the α-subunits of HIF-1 and HIF-2,
which—after nuclear entry—each dimerize with HIF1β and activate
numerous genes. The endothelial response varies with that of many
other cells as both HIF1 and HIF2 become active, while most tissue
cells express only HIF1 subunits. Hypoxia can also induce unfolded
protein stress, which via activation of IRE1 and subsequent steps can
activate IKK and subsequently NFκB. Abbreviations: NOX NADPH
oxidase; other abbreviations are given in the text
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activation, the cellular protein synthesis machinery is
switched to a more energy-saving program, which also can
include the use of intra-ribosomal entry sites for translation
of shorter proteins. Whether hypoxia also affects the
regulation of hemostasis is not sufficiently known; neither
how hypoxia and inflammation cooperate in the endothelial
regulation of hemostasis. While hypoxia can be accompanied
by inflammatory activation, it remains to be established
whether this is due to a direct effect in endothelial cells, or
whether activation of hypoxic monocytes results in a
subsequent inflammatory response. Alternative mechanisms
including unfolded protein stress may also be involved [21].
Manystudiesandreviewshavereportedontheactivationof
endothelial cells by endotoxin and inflammatory cytokines
TNF-αand IL-1.Thesemediators activate endothelialcells via
receptors that activate the classical NFκB pathway (Fig. 1,
upper part). This pathway involves a complex consisting of
NEMO (NFκB essential modulator) with the heterodimer IκB
kinase-α/β (IKKα/IKKβ), which causes phophorylation-
induced detachment and proteasomal degradation of the
inhibitor IκBα,- β and -ε [22]. Displacement of IκB liberates
the p65/p50 complex called NFκB for translocation to the
nucleus. Other combinations of p65 (Rel A) and C-rel on the
one hand with p50 and p52, which are derived from p105 and
p100 NFκB precursor proteins, can also form NFκB. A
similar NFκB activation occurs by toll-like receptors, in
particular TLR-2 and TLR-4 in endothelial cells, which are
domain recognition receptors of the innate immune system.
Their primary role is to recognize common domains in
bacteria and viruses, but they also recognize denatured and
oxidized proteins. The presence of TLR4 was shown on
various endothelial cell types and becomes significantly
increased under inflammatory conditions [23]. TLR2 is also
markedly enhanced by inflammation and, e.g. is present on
endothelial cells of atherosclerotic lesions [24]. Other medi-
ators, such as CD40 ligand and lymphotoxin may activate the
classical NFκB pathway, but stimulate in particular a non-
canonical NFκB pathway. After receptor activation this
pathway includes degradation of the protein TRAF3 and
subsequent NIK- (NFκB inducing kinase)-mediated dimeriza-
tion of IκK, NFκB precursor protein p100 degradation with
release of p52, which complexes with RelB and activates in
the nucleus specific NFκB transcription activation sites [25].
The classical NFκB induces a range of new genes
required for the inflammatory response, such as leukocyte
adhesion molecules E-selectin, VCAM-1 and ICAM-1,
cyclooxygenase-2, and in endothelial cells in vitro tissue
factor, plasminogen activator inhibitor-1, and urokinase-type
plasminogen activator. The availability of NO can counteract
this inflammatory activation in part [26]. As arterial laminar
flow enhances eNOS synthesis and activity, part of its anti-
atherogenic effect regards limiting inflammatory activation of
the endothelium [10, 27]. The non-canonical NFκB pathway
can enforce the inflammatory activation by the classical
NFκB pathway or can modulate it. Finally it should be
mentioned that activation of the TNF-receptor-1 by TNF-α
not only activates NFκB signaling but is also linked via
riboflavin kinase to the activation of NADPH oxidase [28],
which may cause immediate generation of superoxide and cell
activation.
Activation or release of surface-bound proteases, such as
the so-called ADAMTS metalloproteinases, can cause shed-
ding of proteins from the endothelial surface. Shedding of
EPCR and thrombomodulin reduce their availability for
protein C activation [29, 30]. Microparticles with clusters of
endothelial receptors can also be shed from the endothelial
cell [31]. The glycocalyx that contains binding sites for
antithrombin III and other important proteins is markedly
reduced on the microvascular endothelium of diabetes
patients [32] and can be proteolytically affected by hepar-
anase from platelets [33]. The shedded proteins can
sometimes harbor new functions. For example, while
endothelial cells lack the IL-6 receptor, soluble IL-6 receptor
shedded from other cells in severe sepsis can bind to gp130
on endothelial cells and thus induces IL-6 mediated signaling
into endothelial cells, which affects leukocyte extravasation
[34]. Shedded soluble thrombomodulin was shown to protect
ischemic kidneys [35].
Finally, endothelial cells can participate in immune
reactions and acquire high venule endothelial phenotype e.g.
in rheumatoid synovium or in vitro after exposure to
interferon-γ [5, 36].
In vivo verification
Studieson endothelialcells in vitro canbehelpful to challenge
specific questions regarding factors or mechanisms that are
anticipated on the basis of observations in vivo. The findings
must be verified and challenged by the in vivo complexity. In
addition to information that became available from careful
analysis of the background of patients with genetic defects
suffering from thrombotic or bleeding disease, many studies
regarding the functioning of endothelial cells in hemostasis
have originated from the concept that endothelial injury/
dysfunction is an early event in the development of the
atherosclerotic plaque and accompanying studies on the
prevention and removal of arterial thrombi. Factors that
precipitate atherosclerosis may indeed interfere with the
endothelial defense system that actively counteracts the
development of thrombi.
However, as pointed out elegantly by Aird [37], the
vascular bed has different properties and hemostasis require-
ments at various sites and in different tissues. Therefore, it is
important to obtain information at specific sites, such as in
96 Semin Immunopathol (2012) 34:93–106blood brain barrier microvessels which do not express
thrombomodulin, in vascular pockets along vein valves that
may experience stasis and hypoxia, and around glomerular
endothelial cells with their specific fluid dynamics and
interaction with podocytes. The recent availability of mice
models in which the consequences of vascular damage can
be studied in real-time in vivo by dual photon microscopy
[38], in combination with transgenic models overexpressing
or deficient of specific factors, provides a powerful tool that
adds to the existing knowledge obtained from patients with
genetic defects in coagulation or platelet factors and specific
conditions which are prone to thrombosis.
Endothelial control of hemostasis
Table 1 summarizes the main features of hemostasis control
by the endothelium. Endothelial cells act by promoting anti-
coagulant properties and counteracting platelet activation and
aggregation. However, if activated by vasoactive agents, they
release VWF that promotes binding of platelets and t-PA that
enhances control by fibrinolysis. Furthermore, vasoconstric-
tion is an important initial response when the vessel is
damaged. It is caused by direct access of smooth muscle
cells to locally generated vasoactive agents and by bypassing
the vasodilatory action of endothelial cells. Impairment of
these antithrombotic properties of the endothelium either by
g e n e t i co ra c q u i r e dd e f i c i e n c i e so rb ya l t e r a t i o no fe n d o t h e -
lial gene expression in severe inflammation can cause severe
thrombotic complications. The next section shall discuss
these aspects in more detail.
Tissue factor and tissue factor pathway inhibitor
In vivo coagulation requires the availability of the transmem-
brane protein tissue factor, the initiator of the extrinsic
coagulation pathway. Tissue factor dependent signaling is
required for embryo development but dispensible for hemosta-
sis[39]. Its extracellular domain binds and enhances the
proteolytic activity of factor VII, which in turn activates
factor X and factor IX by enzymatic cleavage. Activated
factor X (Xa) subsequently activates prothrombin to thrombin,
the protease that converts fibrinogen into fibrin. The
additional activation of factor IX by factor VIIa is important,
because factor Xa together with factor VIIa are bound to
inhibitory Kunitz domains of the protein tissue factor pathway
inhibitor (TFPI) and become rapidly inhibited together. TFPI
is expressed particularly in microvascular endothelium where
it is bound to its surface [40]. However, it also acts on the
Control of coagulation
Binding of antithrombin III
Thrombomodulin (TM) expression and protein C activation
Expression of endothelial protein C receptor (EPCR)
Release of tissue factor pathway inhibitor (TFPI)
Incidentally: tissue factor induction (in some tumors)
Control of platelet adhesion and activation
Production and acute release of VWF
Cleavage of ULVWF by ADAMTS13
Electrical repulsion by negatively charged heparan sulfates
Reduction of platelet activation by release of NO and PGI2/PGE2
Surface expression of ectonucleotidases
Fibrinolysis
Synthesis and acute release of t-PA
Induction of PAI-1 (in specific activated conditions)
u-PA/UPAR and MT1-MMP (mainly cell invasion)
Platelet disintegration
Thrombin-cleaved ADAMTS18 (C-terminal fragment)
Vasoregulation (in part modulated by endothelial cells)
Constriction as first defence line against acute bleeding
Dilation in an attempt to move an initial thrombus to a smaller tissue area
Table 1 Hemostasis control by
endothelial cells
Abbreviations: VWF von
Willebrand factor, ULVWF
ultra-large VWF, ADAMTS13 a
disintegrin and
metalloproteinase with a
thrombospondin type 1 motif,
member 13, NO nitric oxide,
PGI2 prostacyclin, PGE2
prostaglandin E2, t-PA
tissue-type plasminogen
activator, PAI-1 plasminogen
activator inhibitor-1, u-PA
urokinase-type plasminogen
activator, UPAR u-PA receptor,
MT1-MMP membrane-type
matrix metalloproteinase-1,
C-terminal carboxy-terminal
Semin Immunopathol (2012) 34:93–106 97arterial endothelium, as its deletion also causes increased
ferric chloride-induced arterial thrombosis in mice [41]. The
simultaneously activated factor IXa can activate additional
factor X molecules so that the coagulation pathway can still
proceed when factor VIIa is inactivated.
Tissue factor is present on tissue cells beyond the
microcirculation and in the adventitia and plaques of conduit
vessels. In inflammation and sepsis, it becomes strongly
induced in monocytes-macrophages [42, 43]. Indeed, while
vessel accompanying cells, such as fibroblasts, are the source
of tissue factor in an acutely damaged vessel, monocytes are
the prime source in inflammation and hypoxia. It is true that
inflammatory cytokines rapidly induce tissue factor on
cultured endothelial cells [44], but subsequent in vivo studies
have been unable to detect its expression in vivo in similar
conditions. Only in specific subsets of endothelial cells in
severe sepsis and local flow disturbances in baboons and in
human tumors the presence of tissue factor has been
demonstrated on endothelial cells in vivo [42, 45, 46]. One
study described the presence of tissue factor containing
microvesicles in the basement membrane of endothelial cells
of LPS-stimulated bovine aorta [47]. However, although
recent studies on circulating microparticles indicate the
presence of tissue factor in platelet microparticles, its
presence on in vivo circulating endothelial microparticles,
in contrast to in vitro generated ones, is still uncertain [31,
48, 49]. As pointed out by Mackman [39], the presence of
tissue factor on activated endothelium in vivo may be
alternatively explained as being attributable to the deposition
of monocyte-derived tissue factor-positive microparticles,
similar as demonstrated for granulocytes [50]. Recent studies
on NY1DD sickle mouse, which exhibits a low-TF to high-
TF phenotype switch on exposure to hypoxia/reoxygenation,
suggested that the lack of NO availability can induce TF in
endothelial cells in vivo [51].
It should be noted that tissue factor in the cell
membrane or microparticles is often present in an inactive
form containing unpaired cysteine thiols and requires
conversion of Cys186 and Cys 209 into a disulfide bond
by protein disulfide isomerase to become active. In vivo
data indicated that after laser-induced vessel wall injury
protein disulfide isomerase from endothelial cells rather
than from platelets contributed to the enhanced thrombus
generation [52]. Thus, the endothelial control on the
initiation of coagulation is twofold. In healthy endotheli-
um, TFPI limits TF/VIIa/Xa activity [41]. Furthermore,
while the synthesis of tissue factor by inflammation-
activated endothelial cells in vivo remains uncertain,
endothelial protein disulfide isomerase can enhance the
activity of cryptic tissue factor in circulating micropar-
ticles. Additional roles for this enzyme in the arrangement
of other disulfide interactions are not yet known but cannot
be excluded
Anti-coagulant properties of the endothelium
after thrombin generation
Similarly as factor VIIa needs the membrane-anchored
tissue factor, the activation of prothombin by factors Xa and
X activation by factor IXa require the cofactors Va and
VIIIa, respectively (both activated by thrombin), and the
availability of a negatively charged phospholipids surface.
The latter is provided by platelets once they become
activated by thrombin or by contact with the damaged
vessel wall or tissue. Therefore, once the coagulation has
started to produce thrombin, it becomes highly amplified. It
is therefore important that the endothelial surface provides
several proteins and receptors that inhibit thrombin and
counteract the progress of coagulation.
The potent thrombin inhibitor antithrombin III binds to
specific heparan sulfates of proteoglycans in the glycocalyx
that covers the endothelial surface [53]. Inadequate antithrom-
bin III activity is accompanied by severe thrombotic
complications. Furthermore, a triad of endothelial receptors
is involved in the generation the important anti-coagulant
activated protein C (aPC), which can interrupt the coagulation
cascade by cleavage of factors Va and VIIIa, and in mediating
its cellular anti-inflammatory action. They comprise throm-
bomodulin, the endothelial protein C receptor (EPCR) and
PAR-1, which displays an altered signaling when activated by
the EPCR/aPC complex instead of thrombin.
Thrombomodulin, EPCR, and PAR-1: strong together
Thrombomodulin is synthesized predominantly—but not
exclusively—by endothelial cells. It is ubiquitously
expressed, except for the microvasculature of the brain where
it is undetectable [54]. Thrombomodulin transcription is
enhanced in endothelial cells by arterial shear forces, which
involves the transcription factor KLF-2 [11]. It is reduced by
inflammatory mediators, and can be rapidly decreased by
proteolytic shedding. As a membrane protein is present at the
surface of the endothelial lining, where it catalyzes the
conversion of protein C into aPC by thrombin. This is
facilitated by EPCR, which is abundantly present on
endothelial cells. EPCR binds protein C with high affinity
to the surface of endothelial cells adjacent to the
thrombomodulin-thrombin complex, so that a relatively high
local protein C concentration and effective aPC generation is
achieved. aPC will split and inactivate the cofactors Va and
VIIIa, in part in interaction with protein S, and thereby shut
down continued coagulation. The importance of this pathway
is underscored by the occurrence of thrombosis in patients,
who display (partial) deficiencies in protein C or thrombo-
modulin and in carriers of a factor V variant that is poorly
degraded by aPC, factor VLeiden. Mutations in thrombomo-
98 Semin Immunopathol (2012) 34:93–106dulin can also underlie the occurrence of hemolytic uremic
syndrome in specific patients [55]. Thrombomodulin is also
involved in the activation of tissue-associated fibrinolysis
inhibitor [56], which inactivates complement factor C5a [57].
EPCR does not only bind protein C via its Gla-domain of
protein C but also aPC with equally high affinity [58]. At
appropriate sites of the plasma membrane, namely in the lipid
rafts, the EPCR-aPC couples to PAR-1 [59]. At these sites, the
complex also interacts specifically with caveolin at the inner
side of the plasma membrane [60]. In cultured endothelial
cells 25–30% of PAR-1 is available for such interaction, the
reminder remaining available for thrombin [61]. However,
aPC in the aPC/EPCR complex activates PAR-1 in a different
way than thrombin possibly also involving differences in the
interaction with caveolin. Instead of an activation of PAR-1
via G12/13 proteins, it activates much stronger a Gi protein,
by which anti-inflammatory properties are activated in the
endothelial cell, and probably also in hemopoietic cells.
Inthe context ofits anti-inflammatoryproperties, a number
of studies focused on an improvement of the endothelial
barrier function by aPC. In in vitro studies, activation of
endothelial PAR-1 by interaction with the EPCR-aPC com-
plex caused activation of Gi protein and MAPK phosphory-
lation with subsequent sphingosine-1-phosphate (S-1-P)
generation and cross-activation of the S-1-P receptor-1 [62–
65]. This latter activation leads to activation of Rac-1 [66],
which has endothelial barrier improving properties [4].
Endogenous activated protein C may also limit cancer cell
extravasation by a similar mechanism [67]. Because infusion
of aPC or S-1-P 2 h prior to endotoxin challenge reduced
mortality in mice, this mechanism was considered to be
active in endotoxinemic mice [61]. However, while S-1-P is
known as a barrier stabilizer, also in the absence of aPC [68],
the data on aPC pre-infusion might also be interpreted
differently. Several recent studies indicate that hemopoietic
cells play a role in reducing mortality of endotoxinemia in
animals rather than direct barrier protective properties by
aPC/EPCR/PAR-1-mediated signaling in endothelial cells
[69, 70]. Amelioration of colitis by aPC in mice involved a
reduction of leukocyte adhesion [71], so that the effect may
be even at both the hemopoietic and endothelial cell level.
Endothelial NFκB activity plays a crucial role in multiple
organfailureandtissuedamageinsepsis[72]. As activation of
the endothelial NFκB pathway reduces thrombomodulin and
EPCR expression and increases their shedding from the
endothelial surface, probably by AMADTS-17 activity, such
activation impairs the protein C anti-coagulant mechanism in
endotoxinemia [73]. However, activated protein C protects
endothelial cells and limits its inflammatory activation by
activation of both the non-canonical NFκB pathway and
ERK1,2 activation [74, 75].
The anti-inflammatory activation of PAR-1 by aPC adds
to the well known PAR-1 activation by thrombin, which in
endothelial cells induces a number of cellular responses that
counteract the thrombotic response that is initiated by
thrombin (Fig. 2). Thrombin activation of PAR-1 induces
several routes of intracellular signaling, by which (a) nitric
oxide (NO) and prostacyclin production are enhanced,
which cause vasodilation and limit platelet activation; (b)
t-PA is released that binds to the fibrin generated and causes
effective fibrinolysis; and (c) Weibel–Palade bodies are
activated that release VWF, angiopoietin-2, and P-selectin,
the latter two also enhancing a subsequent inflammatory
response by PMNs. All these reaction occur within minutes.
The precise extent of the various aspects of this response,
also called acute response, can vary between different types
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NO, prostacyclin, and t-PA. The number of Weibel–Palade
bodies also can vary between different types of vessels.
VWF release and control of its ultra-large multimers
VWF is the major protein of the Weibel–Palade body and
its multimers cause a striped structure when visualized in
the electron microscope [76]. VWF is only synthesized in
endothelium and megakaryocytes and present in α-granules
of platelets. After synthesis in the endothelial endoplasmic
reticulum, VWF is processed in the Golgi complex. By the
lower pH in the terminal Golgi complex, VWF molecules
form back to back dimers, which subsequently become
spontaneously packed as multimers in a spiral-like fashion
[77]. In this way, the specific Weibel–Palade body is
formed, which remains the storage organelle for VWF until
its release into the blood. Basal secretion of VWF proceeds
via the same route [78]. Besides VWF, P-selectin and
angiopoietin-2 are deposited in and released from the
Weibel–Palade bodies [79, 80]. Furthermore, several other
proteins can be encountered in the Weibel–Palade bodies,
such as t-PA and IL-8, but only a small fraction of these
proteins is stored in this specific organelle.
VWF can be released from the endothelial cells by
vasoactive agents, such as histamine, bradykinin, and vaso-
pressin, and thrombin, which enhance cytoplasmic calcium
concentration and activate protein kinase C. During this
release process, that occurs within 5–10 min single and
clusters of Weibel–Palade bodies fuse with the plasma
membrane and release VWF [81, 82]. If the endothelial cells
are stimulated by cAMP-elevating agents, only a part of the
Weibel–Palade bodies is released that contain VWF, but little
P-selectin [83]. Probably by the exposure to the neutral pH
of the blood, VWF is unfolding and so-called ultra-large
VWF multimers (ULVWF) are formed on the surface of the
endothelium, which can amount up to several mm in length,
when formed by combination of the VWF content of several
Weibel–Palade bodies. These ULVWF multimers align along
the surface of the endothelium or damaged vessel, and are
able to bind platelets directly by interaction of their VWF-A1
domains with platelet GpIbα moieties. Under high shear
forces, platelet GpIIb can bind to VWF-A3 domains.
On the surface of the endothelium, these ULVWF
multimers are cut in smaller multimers by the action of
the metalloproteinase ADAMTS13, which stands for a
disintegrin-like and metalloprotease with thrombospondin
type 1 repeats-13 [84]. ADAMTS-13 binds to the VWF-A3
domain and cuts individual VWF molecules at a specific
site (Tyr1605-Met1606) within the VWF-A2 domain. This
proteolytic activity, which is facilitated by ADAMTS13
binding to the endothelial surface, results within minutes in
the generation of shorter VWF multimers and a conversion
of the extended strings of ULVWF into smaller more
globular VWF multimers of less than 20 μm. Hence, VWF
multimers with variable length become circulating in
plasma but once detached into the circulation the binding
and cleavage sites for ADAMTS13 on the A2-A3 domains
of VWF multimers or platelet-VWF complexes is buried in
its round-up structure and becomes only available again
under high fluid shear forces [85].
ADAMTS13
ADAMTS13 is synthesized in liver stellate cells, endothelial
cells, and present in platelets. Furthermore, itis synthesized in
kidney podocytes and deposited in the glomerular basement
membrane, where it may have a specific function in
preventing thrombus formation. Given the overall mass of
endothelial cells in the body, one may anticipate that
endothelial cells have a considerable if not major contribution
to the production of ADAMTS13 in the blood. ADAMTS13
isalsoactivewhenitstillcontainsitspropeptide,andperforms
activity when appropriately bound to VWF [86].
ADAMTS13 bound to endothelial cells exhibited enhanced
cleavage of VWF. This binding involves the C-terminal
thrombospondin domain ADAMTS13 and occurred indepen-
dently of VWF [87]. Davis et al. [88] suggested that CD36 is
a good candidate for this binding. These data may underlie
the observations that trombospondin-1—by competition—
protects VWF from cleavage by ADAMTS13 [89] and may
bear impact on the observation that CD36 antibodies were
found in patients with hemolytic uremic syndrome [90].
In addition to deficiency of ADAMTS13 activity by
mutation or generation of auto-antibodies, a partial reduction
of ADAMTS-13 activity due to reduced synthesis has been
reported in severe inflammatory conditions, although the extent
of this reduction varies between different studies [91, 92]. A
suppressive effect of inflammatory mediators is underscored
by the findings that endotoxin infusion in healthy human
volunteers caused a 36% decrease of ADAMTS13, in addition
to an increase in VWF [93] and by a short report showing that
ADAMTS13 mRNA and proteolytic activity was reduced by
interferon-γ,T N F - α and interleukin-4 in rat primary hepatic
stellate cells and human endothelial cells in vitro [94].
Animal studies may provide additional information.
ADAMTS13 deficiency in mice results in a prothrombotic
phenotype and VWF platelet strings in histamine-stimulated
mesenteric veins but not in arterioles [95]. In addition, it also
slows down leukocyte rolling in these vessels, and increased
influx of PMNs in thioglycolate-induced peritonitis and into
skin tissue in excision wounds [95]. Shiga toxin triggers TTP
in a subset of ADAMTS13-deficient mice, but this response
required an additional triggering event [96]. The smaller Shiga
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induce VWF secretion and thrombotic microangiopathy in
ADAMTS-deficient mice [97]. On the other hand,
ADAMTS13 inhibition in baboons was sufficient to cause
TTP in the absence of inciting triggers [98].
Interruption of platelet activation and vasodilation
Platelets are normally repelled from the surface of the
endothelium by the negatively charged glycosaminoglycans,
but this defense can be overcome in activated platelets by
receptor-ligand interactions, namely the binding of P-selectin
to the protein PSGL-1 that bears P-selectin sugar ligands,
binding of GpIbα to either P-selectin or VWF on the surface
ofthe endothelium,and indirectlyvia a fibrinbridgethat joins
GpIIb/IIIaandICAM-1.Plateletheparanase,whichisreleased
from activated platelets, can facilitate this interaction by
degrading proteoglycans in the endothelial glycocalyx.
Endothelial cells actively prevent or limit thrombus
formation by suppressing platelet adhesion and activation
[99]. The surface of endothelial cells harbors ectonucleoti-
dases (CD39), which rapidly convert the platelet-stimulating
ADP into adenosine [100]. Platelet activation is counteracted
by prostacyclin and prostaglandin E2, which are liberated
from the endothelium after stimulation by vasoactive agents
and thrombin. Prostacyclin is produced by the endothelium
of large vessels, while the endothelial cells from smaller
vessels produce predominantly prostaglandin E2 [101]. The
effect of prostacyclin is enhanced by nitric oxide, which is
produced by endothelial nitric oxide synthase (eNOS). Nitric
oxide production is rapidly enhanced after exposure of
endothelial cells to vasoactive agents that enhance the
cytosolic calcium ion concentration, and by exposure of the
endothelium to arterial shear forces, which induce eNOS
synthesis and enhance its activity by phosphorylation of Ser
1177 (Ser1179 in mouse) [102, 103].
The importance of NO as antithrombotic mediator was
also demonstrated in a recent study on the prothrombotic
effect of antiphospholipid antibodies in mice [104]. The
antiphospholipid syndrome is accompanied by recurrent
thrombosis. Ramesh et al. [104] showed that interaction of
the complex between a dimer of β2-glycoprotein-1 and
antiphospholipid antibody interacts with the LDL-binding
domain of the so-called apoER2 lipoprotein receptor by
which the protein phosphatase PP2A was activated and
eNOS was dephosphorylated at its Ser1179 site. This
reduced NO production markedly and resulted in increased
leukocyte adhesion to endothelial cells and increased
tendency to thrombus formation.
It should be noted that nitric oxide, prostacyclin, prostaglan-
din E2, and adenosine also induce vasodilatation. While
vasoconstriction is a first response of a damaged vessel to limit
blood loss, rapid vasodilation can help to limit the area of
ischemia once an initial thrombus h a sb e e nf o r m e di nt h ea r t e r i a l
leg of the circulation. By immediate vasodilatation, a new
thrombus may move to a more distal part of the vascular tree, so
that it will cause ischemia in a smaller area, in particular if such a
thrombus passes across a branch point of the distal vessel.
Disintegration of platelet aggregates
The previous mechanisms all aim at preventing platelet
activation and aggregation. Interestingly, a recent study pointed
to an additional mechanism in thrombin-activated endothelial
cells that is aimed at disintegrating platelet aggregates that have
already been formed [105]. Thrombin not only enhances the
secretion of ADAMTS18, but also uncovers by proteolytical
cleavage a new activity in the obtained 45 kD C-terminal part
of ADAMTS18. The C-terminal ADAMTS18 fragment that
is generated contains a newly exposed 18mer moiety that
binds to platelet GPIIIa49-66. By this interaction, platelet
aggregates become destroyed by oxidative platelet fragmen-
tation. This was not only observed in vitro, but the
ADAMTS18 fragment also limited FeCl3-induced carotid
artery thrombosis in mice as well as cerebral infarction in a
murine postischemic stroke model in vivo [105].
Fibrinolysis
Endothelial cells also provide a mechanism that counteracts
the accumulation fibrin, the product of coagulation. To that
end, endothelial cells produce t-PA, the prime regulatory
component for activating the fibrinolytic system in blood and
bodycavities [106]. Both single-chain and double-chain t-PA
activate the liver-derived zymogen plasminogen into plas-
min, but t-PA requires binding to fibrin before it obtains
activity. The broadly acting protease plasmin subsequently
degrades fibrin into fibrin degradation products. Endothelial
cells produce and release continuously t-PA, which is cleared
within 10–15 min by the liver, unless it has encountered
fibrin to which it binds. In this way t-PA monitors the
patency of blood vessels and removes via fibrinolysis hidden
deposition of fibrin in the vessels. Furthermore, t-PA
becomes acutely released from storage organelles after
exposure of endothelial cells to vasoactive agents or
thrombin. The high availability of t-PA at the moment that
a fibrin network is forming ensures the binding of t-PAwithin
the clot, by which it is much more effective in fibrinolysis
than when t-PA is added from the outside to an existing clot.
There exists some dispute about the nature of the storage
vesicles for t-PA [107, 108]. Although t-PA has been
encountered in Weibel–Palade bodies, it is generally believed
that this represents only a minor fraction of t-PA in the
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for inducing adequate acute release of t-PA in endothelial
cells,Emeisetal.[107] demonstrated that t-PAwas present in
specific vesicles, that were separate of the VWF containing
Weibel–Palade bodies and other endothelin-containing
vesicles. These “Emeisosomes” are probably involved in
both basal and induced release of t-PA.
In the absences of plasminogen MT1-MMP also can act as a
fibrinolysin [109]. Furthermore, endothelial can synthesize a
second plasminogen activator, urokinase-type (u-PA), when
they are activated by inflammatory cytokines, such as TNF-α,
IL-1, endotoxin, or lymphotoxin [110]. Its activity is confined
to the cell surface by the urokinase receptor (UPAR) [111]. It
isgenerallybelievedthatMT1-MMPandu-PAplayimportant
roles in pericellular proteolysis during cell migration, matrix
invasion,andangiogenesis[112–114] .u - P Ab o u n dt oU P A Ri s
also involved in leukocyte and progenitor cell migration
invasion, which may underlie the observation that selective
abrogation of the u-PA/UPAR interaction plays a pivotal role
in the suppression of chronic inflammation to exacerbated
fibrin deposition [115].
Both the activity of t-PA and u-PA are inhibited by
plasminogen activator-1 (PAI-1). PAI-1 is produced in large
amountsbycytokine-stimulatedculturedendothelialcells,but
thecontributionofendothelialPAI-1invivohasbeendebated.
Platelets contain PAI-1, and liver and adipose tissue cells
r e s p o n dt oc y t o k i n e sT N F - α and TGF-β by enhanced
production of PAI-1 [44, 116, 117]. PAI-1 can also interact
with aPC [118, 119], but the physiological meaning of this
interaction is less clear. Interestingly, PAI-1 is secreted as an
active molecule but rapidly loses its activity, probably by
exposure to the more oxidative environment which induces a
structural change. When PAI-1 interacts with u-PA, the
complex is cleared by UPAR. In this way, the large
availability of PAI-1 and UPAR can reduce the u-PA
concentration in the environment of the cell.
Haemostasis and inflammation in tissue repair
and angiogenesis
The haemostatic plug not only acts as a sealing of the tissue
after wounding, but also as the scaffolding for invading cells
during the subsequent healing process. Thrombin can also be
considered as a growth factor and can stimulate angiogenesis
and vascular remodeling. Activated protein C has anti-
apoptotic properties for endothelial cells. The transient fibrin
matrix is an excellent matrix for endothelial cells to act as
scaffolding for new capillary structures [120, 121]. The
presence of a fibrinous exudate can facilitate the angiogenesis
process by providing factors and matrix for the invasion and
expansion of new microvessels. Angiogenesis is induced by
angiogenic growth factors often in combination with inflam-
matory mediators or other factors induced by ischemia or
secreted by platelets. Furthermore, several fibrin degradation
products can activate or protect the endothelium [122–125].
In addition to their pivotal role in the formation of the
hemostatic plug, platelets facilitate tissue repair and inflam-
mation. Platelets are a rich source of factors that stimulate
tissue repair and facilitate interaction between leukocytes and
endothelial cells. They accumulate and release, after activa-
tion, many vasoactive agents and chemokines, such as
serotonin, thromboxane A2, platelet activating factor and
RANTES,andangiogenicgrowthfactors,inparticularVEGF,
that is secreted in a potent fibronectin-bound form [126].
These factors are stored in α-granules and released upon
activation of the platelet [127]. Interestingly, angiogenesis
inhibiting proteins, such as thrombospondin-1 and endo-
statin, are stored in separate granules in the same platelet
[127]. Thus, platelets are potentially powerful regulators of
tissue repair associated angiogenesis.
After stimulation, platelets also release P-selectin from a
specific area in the α-granules which then becomes expressed
on their surface. P-selectin plays an important role in the
recruitment of platelets on neutrophils and monocytes and in
their interaction with endothelial cells [128, 129]. Finally,
activated platelets also produce and expose CD40 ligand
(CD40L or CD154), which can interact with leukocytes or
activate the non-canonical NFκB pathway in endothelial
cells and thus enhance the expression of leukocyte receptors
and enhance the production of chemokines MCP-1 and
interleukin-8 [130]. In this way, platelet play important roles
in inflammation and sepsis, as well as in immunoregulation,
such as occurs in the atherosclerotic plaque [129, 130].
Conclusions
By its strategic position at the interface between blood and
tissues, the endothelium controls blood fluidity and contin-
ued tissue perfusion while at the same time it directs
recruitment of inflammatory cells to areas that need defense
or repair. From the foregoing discussion, it becomes clear
that endothelial cells at different sites in the body achieve a
delicate fine tuning, by which coagulation, thrombus
formation, and inflammation are kept in balance and
adapted to the local needs. Notwithstanding, these balances
can become disturbed in by genetic, immunologically
acquired deficiencies and by overreactions to microbes
and toxins. Better understanding of the underlying mech-
anisms that contribute to thrombotic and inflammatory
disease will be the basis for further development of
effective treatments to combat these complications. At the
same time, it is fascinating how delicately the interaction
between hemostasis and inflammation is regulated by the
endothelium.
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